Research Progress on RAGE/LRP1 Transporters At the Blood-Brain Barrier and the Neurovascular Unit in Alzheimer’s Disease

Abstract

Abstract: The blood cerebrospinal fluid barrier (blood-CSF barrier) existed between peripheral and central nervous system (CNS) plays critical roles in the maintenance of CNS homeostasis. Emerging evidence suggests that blood-CSF barrier is closely related to the development and pathogenesis of Alzheimer’s disease (AD). This review discusses the role of receptor for advanced glycation end products (RAGE), low density lipoprotein receptor-related protein 1 (LRP1) transporters, and the neurovascular unit (NVU) mediated central β-amyloid protein regulation in the pathogenesis of AD, providing new prevention and treatment strategies for AD.

Key words: blood cerebrospinal fluid barrier (blood-CSF barrier), &, beta, -amyloid protein (A&, beta, ), Alzheimer&, rsquo, s disease (AD), RAGE/LRP1 transporters, neurovascular unit

WANG Hao, DU Guan-tao, LIU Guang-jun, HONG Hao. Research Progress on RAGE/LRP1 Transporters At the Blood-Brain Barrier and the Neurovascular Unit in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2015, 5(2): 38-45.

References

[1] Henry W Querfurth, Frank M LaFerla. Alzheimer's Disease [J]. N Engl J Med, 2010, 362(4):329-344.

[2] Jean Francois Dartigues . Alzheimer's disease: a global challenge for the 21st century [J]. Lancet Neurol, 2009, 8(12):1082-1083.

[3] David A Bennett, Yu Lei, Yang Jing-yun, et al. Epigenomics of Alzheimer's disease [J]. Transl Res, 2015, 165(1):200-220.

[4] Ignacio F Mata, James Leverenz, Daniel Weintraub, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease [J]. JAMA Neurol, 2014, 71(11):1405-1412.

[5] Moses N Wainaina, Chen Zhi-chun, Zhong Chun-jiu. Environmental factors in the development and progression of late-onset alzheimer'sdisease [J]. Neurosci Bull, 2014, 30(2):253-270.

[6] Irwin David J, Cohen Todd J, Grossman Murray, et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies [J]. Brain, 2012, 135(Pt 3):807-818.

[7] S Sakura Minami, Min Sang-Won, Grietje Krabbe, et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models [J]. Nat Med, 2014, 20(10):1157-1164.

[8] Tara L Spires-Jones, Bradley T Hyman. The intersection of amyloid beta and tau at synapses in Alzheimer's disease [J]. Neuron, 2014, 82(4):756-771.

[9] Min-Kyoo Shin, Hong-Gi Kim, Seung-Hyun Baek, et al. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques [J]. Neurobiol Aging, 2014, 35(5):990-1001.

[10] Mar Cuadrado-Tejedor, Ana Ricobaraza, Diana Frechilla, et al. Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice [J]. J Alzheimers Dis, 2012, 28(3):567-578.

[11] Christopher Exley, Emily House, Anthony Polwart, et al. Brain burdens of aluminum, iron, and copper and their relationships with amyloid-β pathology in 60 human brains [J]. J Alzheimers Dis, 2012, 31(4):725-730.

[12] Ignacio Pedrós, Dmitry Petrov, Michael Allgaier, et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease [J]. Biochim Biophys Acta, 2014, 1842(9):1556-1566.

[13] Cristian Ripoli, Sara Cocco, Donatella Li Puma, et al. Intracellular accumulation of amyloid-β (Aβ) protein plays a major role in Aβ-induced alterations of glutamatergic synaptic transmission and plasticity [J]. J Neurosci, 2014, 34(38):12893-12903.

[14] Cao Lu-xiang, Benjamin R Schrank, Steve Rodriguez, et al. Aβ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo [J]. Nat Commun, 2012, 3:1009.

[15] Michael A Castello, Salvador Soriano. On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis [J]. Ageing Res Rev, 2014, 13:10-12.

[16] Michelle A Erickson, William A Banks. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease [J]. J Cereb Blood Flow Metab, 2013, 33(10):1500-1513.

[17] Birgit Obermeier, Richard Daneman, Richard M Ransohoff. Development, maintenance and disruption of the blood-brain barrier [J]. Nat Med, 2013, 19(12):1584-1596.

[18] William M Pardridge, Triguero D, Yang J, et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier [J]. J Pharmacol Exp Ther, 1990, 253(2):884-891.

[19] Maria Feldmann, Marie Claude Asselin, Joan Liu, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study [J]. Lancet Neurol, 2013, 12(8):777-785.

[20] Ronit Shaltiel-Karyo, Moran Frenkel-Pinter, Edward Rockenstein, et al. A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD) [J]. J Biol Chem, 2013, 288(24):17579-17588.

[21] Sun-Young Kook, Hyun Seok Hong, Minho Moon, et al. Disruption of blood-brain barrier in Alzheimer disease pathogenesis [J]. Tissue Barriers, 2013, 1(2):e23993.

[22] Raj N Kalaria. Vascular factors in Alzheimer's disease [J]. Int Psychogeriatr, 2003, 15(Suppl 1): 47-52.

[23] Paul A Yates, Patricia Desmond, Pramit M Phal, et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease [J]. Neurology, 2014, 82(14):1266-1273.

[24] Anika M S Hartz, Bjorn Bauer, Emma L B Soldner, et al. Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy [J]. Stroke, 2012, 43(2):514-523.

[25] Honjo K, Black S E, Verhoeff N P. Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade [J]. Can J Neurol Sci, 2012, 39(6):712-728.

[26] Rashid Deane, Du Yan Shi, Ram Kumar Submamaryan, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain [J]. Nat Med, 2003, 9(7):907-913.

[27] Masayoshi Shibata, Shinya Yamada, S Ram Kumar, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier [J]. J Clin Invest, 2000, 106(12):1489-1499.

[28] Douglas Galasko, Joanne Bell, Jessica Y Mancuso, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease [J]. Neurology, 2014, 82(17):1536-1542.

[29] Michael O Chaney, W Blaine Stine, Tyler A Kokjohn, et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling [J]. Biochim Biophys Acta, 2005, 1741(1-2):199-205.

[30] Ottavio Arancio, Zhang Hui-ping, Chen Xi, et al. RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice [J]. EMBO J, 2004, 23(20): 4096-4105.

[31] Fumitaka Shimizu, Yasuteru Sano, Osamu Tominaga, et al. Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-β by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro [J]. Neurobiol Aging, 2013, 34(7):1902-1912.

[32] Nicola Origlia, Massimo Righi, Simona Capsoni, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction [J]. J Neurosci, 2008, 28(13):3521-3530.

[33] Alexander Slowik, Julika Merres, Anne Elfgen, et al. Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)--and amyloid beta 1-42-induced signal transduction in glial cells [J]. Mol Neurodegener, 2012, 7:55.

[34] Bjoern Von Einem, Daniel Schwanzar, Florian Rehn, et al. The role of low-density receptor-related protein 1 (LRP1) as a competitive substrate of the amyloid precursor protein (APP) for BACE1 [J]. Exp Neurol, 2010, 225(1):85-93.

[35] Alberto Lleó, Elaine Waldron, Christine A F von Arnim, et al. Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase [J]. J Biol Chem, 2005, 280(29):27303-27309.

[36] Furu Liang, Jia Jian-ping, Wang Shu-ying, et al. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease [J]. J Clin Neurosci, 2013, 20(3):357-361.

[37] Berislav V Zlokovic, Rashid Deane, Abhay P Sagare, et al. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain [J]. J Neurochem, 2010, 115(5):1077-1089.

[38] Philip Verghese, Joseoh M Castellano, Kanchan Garai, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions [J]. Proc Natl Acad Sci USA, 2013, 110(19):E1807-16.

[39] Rashid Deane, Abhay Sagare, Katie Hamm, et al. ApoE isoform-specific disruption of amyloid β peptide clearance from mouse brain [J]. Clinical Investigation, 2008, 118(12):4002-4013.

[40] Takahisa Kanekiyo, John R Cirrito, Liu Chia-Chen, et al. Neuronal clearance of amyloid-β by endocytic receptor LRP1 [J]. J Neurosci, 2013, 33(49):19276-19283.

[41] Berislav V Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders [J]. Nat Rev Neurosci, 2011, 12(12):723-738.

[42] Constantin Bouras, Eniko Kövari, Francois Herrmann, et al. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status [J]. J Neuropathol Exp Neurol, 2006, 65(3):235-244.

[43] Gregory J Del Zoppo. Stroke and neurovascular protection [J]. N Engl J Med, 2006, 354(6):553-555.

[44] Cárdenas A, Kong M, Alvarez A, et al. Signaling pathways involved in neuron-astrocyte adhesion and migration [J]. Curr Mol Med, 2014, 14(2):275-290.

[45] Koji Ishitsuka, Teteuro Ago, Koichi Arimura, et al. Neurotrophin production in brain pericytes during hypoxia: a role of pericytes for neuroprotection [J]. Microvasc Res, 2012, 83(3):352-359.

[46] Markus Ramsauer, Dorothee Krause, Rolf Dermietzel. Angiogenesis of the blood-brain barrier in vitro and the function of cerebral pericytes [J]. FASEB J, 2002, 16(10):1274-1276.

[47] Yoshiaki Itoh, Haruki Toriumi, Satoshi Yamada, et al. Astrocytes and pericytes cooperatively maintain a capillary-like structure composed of endothelial cells on gel matrix [J]. Brain Res, 2011, 1406:74-83.

[48] Takayuki Nakagomi, Shuji Kubo, Akiko Nakano-Doi, et al. Brain Vascular Pericytes following Ischemia have Multipotential Stem Cell Activity to Differentiate into Neural and Vascular Lineage Cells [J]. Stem Cells, 2015, doi: 10.1002/stem.1977.

[49] Fiona M Laird, Cai Huai-bin, Alena Savonenko, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions [J]. J Neurosci, 2005, 25(50):11693-11709.

[50] Stephen F Carter, Michael Scholl, Ove Almkvist, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-Ldeprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG [J]. J Nucl Med, 2012, 53(1):37-46.

[51] Arundhati Jana, Kalipada Pahan. Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease [J]. J Neurosci, 2010, 30(38):12676-12689.

[52] Li C, Zhao R, Gao K, et al. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease [J]. Curr Alzheimer Res, 2011, 8(1):67-80.

[53] Natalia N Nalivaeva, Caroline Beckett, Nikolai D Belyaev, et al. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? [J]. J Neurochem, 2012, 120(Suppl 1):167-185.

[54] Killick R, Ribe E M, Al-Shawi R, et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway [J]. Mol Psychiatry, 2014, 19(1):88-98.

[55] Yao Jun, Du Heng, Yan Shi-qiang, et al. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease [J]. J Neurosci, 2011, 31(6):2313-2320.

[56] Sandra D Mulder, Robert Veerhuis, Marinus A Blankenstein, et al. The effect of amyloid associated proteins on the expression of genes involved in amyloid-beta clearance by adult human astrocytes [J]. Exp Neurol, 2012, 233(1):373-379.

[57] Eric Karran, John Hardy. Antiamyloid therapy for Alzheimer’s disease — are we on the right road? [J]. N Engl J Med, 2014, 370(4):377-378.